In particular, approximately 17% of patients with HER2-low primary breast cancer exhibited conversion to HER2-zero after neoadjuvant therapy, whereas about 38% of patients with HER2-zero in the primary tumour switched to HER2-low, further confirming the instability of HER2-low expression. The gene discussed is ERBB2; the disease is breast cancer.